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The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in
stage II colon cancer. Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV
(100mgm
 2 LVþ450mgm
 2 5-FU weekly, weeks 1–6, in 8 weeks cycles 7) or surveillance only. Five hundred patients were
evaluable for analyses. After a median follow-up of 95.6 months, 55 of 252 patients (21.8%) have died in the 5-FU/LV arm and 58 of
248 patients (23.4%) in the surveillance arm. There was no statistically significant difference in overall survival (OS) between the two
treatment arms (hazard ratios, HR 0.88, 95% CI 0.61–1.27, P¼0.49). The relative risk for tumour relapse was higher for patients on
the surveillance arm than for those on the 5-FU/LV arm; however, this difference was not statistically significant (HR 0.69, 95% CI
0.45–1.06, P¼0.09). Consequently, disease-free survival (DFS) was not significantly different between the two trial arms. In
conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II
colon cancer. However, in this study with limited power to detect small differences between the study arms, adjuvant chemotherapy
failed to significantly improve DFS and OS.
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Colorectal cancer is the leading cause of cancer-associated deaths
in the Western world. Up to 50% of patients with colorectal cancer
who undergo potentially curative surgical treatment develop
metastatic disease leading to incurability and death (Parkin et al,
2001; Jemal et al, 2003). The most important prognostic factors
influencing the survival of patients with colon cancer are tumour
stage determined by the extent of tumour invasion into the bowel
wall and involvement of regional lymph nodes. According to the
International Union Against Cancer (UICC), stage II colon cancer
is defined by tumour penetration through the bowel wall with
invasion into the subserosa or deeper, but no regional lymph node
involvement nor distant metastases. The overall survival (OS) rate
of patients with stage II colon cancer after curative surgery alone is
approximately 70–80% (Nauta et al, 1989). In patients with stage
III colon cancer, as defined by the presence of regional lymph node
metastases, several trials have shown adjuvant chemotherapy to
improve survival (Moertel et al, 1990, 1995; Andre et al, 2004). The
benefit of adjuvant chemotherapy for patients with stage II disease
is still a matter of controversy. Results of a single randomised trial
failed to demonstrate an improvement of OS by adjuvant
chemotherapy in patients with stage II colon cancer (Moertel
et al, 1995). The results of pooled analyses of data from four
National Surgical Adjuvant Breast and Bowel Project (NSABP)
adjuvant studies and of the International Multicentre Pooled Analysis
of B2 Colon Cancer (IMPACT B2), including several trials with stage
II colon cancer patients, demonstrated controversial results with
regard to the survival benefit achieved by adjuvant chemotherapy
(IMPACT B2 Investigators, 1999; Mamounas et al, 1999).
The purpose of the trial reported here, initiated and conducted
by the Austrian Breast and Colorectal Cancer Study Group
(ABCSG), was to examine the impact of adjuvant chemotherapy
with 5-fluorouracil (5-FU) and leucovorin (LV) on OS and disease-
free survival (DFS) in patients following curative surgery for stage
II colon cancer.
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sMATERIALS AND METHODS
This multicentre phase III trial involved 31 participating hospitals.
The protocol was approved by the ethics committees at the
participating institutions. Enrolment of patients began in November
1993 and was finished in June 2003.
Patient selection
To be eligible for this study, patients had to fulfil the following
inclusion criteria: written informed consent to participate in this
trial, histologically proven stage II colon carcinoma according to
the UICC (T3-T4, N0, M0), potentially curative resection without
gross or microscopic evidence of residual disease, age between 18
and 80 years, World Health Organization (WHO) performance
status of 0 or 1, absence of severe concomitant disease and other
malignancies, and adequate bone marrow, renal and hepatic
function. The following were applied as exclusion criteria: prior or
concomitant chemotherapy, immunotherapy or radiotherapy, and
carcinoma of the rectum defined as tumour below the anatomical
rectosigmoidal borderline or within 16cm from the anal verge
measured by a non-flexible rectoscope. Other exclusion criteria
included the presence of metastasis or an interval exceeding 42
days between surgery and the start of adjuvant therapy.
Written informed consent was obtained from all patients
participating in this trial.
Monitoring visits were performed regularly at the participating
centres to inspect the original data concerning eligibility and to
review documented chemotherapy and follow-up data.
Surgical treatment
A tumour of the caecum, the ascending colon, or the hepatic
flexure was resected with a right hemicolectomy, resecting the
right colic artery and the ileocolic artery. A tumour of the colon
transversum was treated by resection of the appropriate part of the
colon including the hepatic and splenic flexure. Carcinomas of the
descending colon were resected by a left hemicolectomy including
the left colic artery. Finally, sigmoid tumours were treated by a
sigmoid resection including the inferior mesenteric blood vessels.
The protocol required precise removal of locoregional lymph
nodes.
Randomisation and stratification procedures
Treatment allocation was obtained by contacting the central
randomisation office by telephone. Randomisation was performed
by computer assigning the patients to one of two post-operative
treatment arms: (1) 5-FU/LV, (2) surveillance only. The method of
Pocock and Simon (1975) was employed to marginally balance the
following criteria: gender, age (p65 vs 465–80 years), tumour
size (T3 vs T4), tumour differentiation (G1/2 vs G3/4), and centre.
Chemotherapy
In the chemotherapy arm (study arm 1), patients received adjuvant
therapy consisting of LV 100mgm
 2 administered as an
intravenous bolus, followed by 5-FU 450mgm
 2 as an intravenous
short infusion over 15min given once weekly for 6 weeks in each
8-week cycle for a total of seven cycles (¼56 weeks of therapy). As
per protocol, adjuvant chemotherapy was required to be started
within 42 days after tumour resection. In the control arm (study
arm 2), patients were assigned to surveillance only.
In study arm 1, dose modifications were required for
haematological or other severe toxicity. According to the protocol,
the 5-FU dosage was reduced to 350mgm
 2 for subsequent
therapy cycles when patients developed grade II toxicity according
to the WHO criteria. In case of occurrence of WHO grade III
toxicity, chemotherapy was delayed for 1 week and continued with
5-FU at a dosage of 350mgm
 2. Chemotherapy was discontinued
in any case of WHO grade IV toxicity, or when grade III toxicity
re-occurred in spite of previous 5-FU dose reduction. In case of
leucopenia and/or thrombocytopenia, continuation of chemother-
apy was delayed until a whole leucocyte count of X3.0 10
9l
 1
and/or a platelet count of X100 10
9l
 1 was reached.
Follow-up
Patients were evaluated every 3 months during the first year post-
randomisation (¼treatment period in arm 1), every 6 months
during years 2–5, and once yearly until year 10 after randomisa-
tion. A physical examination with evaluation of body weight and
performance status, determination of blood count, serum liver
function parameters, carcinoembryonic antigen and tests for
occult blood in stool, as well as chest radiography and
ultrasonography of the liver were performed at each follow-up
visit. Colonoscopy was required every 6 months during the first
6 years after randomisation, then once a year.
Statistical methods
The trial was designed to detect a difference in OS of 10% between
the two study arms (70 vs 80%) with a power of 85% and a two-
sided significance level of 0.05, so that approximately 318 patients
would be recruited to each arm in 3 years. The final analysis was
planned 7 years after the study began. After 535 patients had been
accrued, recruitment was stopped ahead of schedule for low
accrual rates.
All patient data were collected at the Study Group’s central data
office and processed and analysed applying SAS software (SAS
Institute, Cary, NC, USA). Distribution of prognostic factors to the
treatment arms was described with frequencies for categorial
variables and with medians for continuous data and tested with the
w
2-test and Kruskal–Wallis test, respectively.
Overall survival was defined as the interval between date of
randomisation and date of last visit or date of death, independent
of the cause of death. Disease-free survival was defined as the
interval between randomisation and either recurrence of colon
cancer, occurrence of metastases, occurrence of a second primary
cancer, or death without evidence of recurrence, or date of last
visit.
Cancer-specific survival was defined as the interval between date
of randomisation and date of last visit or date of death caused by
colon cancer.
Overall survival, DFS, and cancer-specific survival were
estimated and graphically presented according to the method of
Kaplan and Meier (1958). Differences between curves were
assessed by the Mantel log-rank test for censored survival data
(Mantel, 1966). The Cox proportional hazards model (Cox, 1972)
was used to assess the prognostic values of treatment, gender, age,
tumour grading, tumour stage, tumour localisation, and number of
surgically removed lymph nodes in univariate and multivariate
analyses, quantifying their effect by hazard ratios (HR). Backward,
forward, and stepwise procedures were used and compared to
identify the final model with a threshold of 10% for the variables to
stay in or enter the model. The results were solid and the results
were taken from the stepwise procedure. Corresponding 95%
confidence intervals (CI) are also given. All P-values given are two
sided.
RESULTS
Patient characteristics
A total of 535 patients were included in this prospective
randomised trial. Thirty-three randomised patients were found
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Ineligibility of patients was determined by the central data
monitoring committee of this trial. The reasons for ineligibility
of patients in the two study arms are shown in Table 1. Two
patients were not evaluable for analysis for lack of follow-up data.
Statistical analyses were performed with the data of the remaining
500 eligible and evaluable patients according to the intention-to-
treat principle. Baseline patient and tumour characteristics are
reported in Table 2. The patient and tumour characteristics were
well balanced between the two study arms. The median follow-up
time for the study population was 95.6 months (range 0–148.9
months).
The median number of lymph nodes resected was 17 (range 5–68).
Treatment adherence
Adjuvant chemotherapy with seven cycles of 5-FU/LV as planned
in the protocol was administered to 164 of 252 (65.1%) evaluable
patients on the chemotherapy arm. Seven (2.8%) patients on study
arm 1 received no chemotherapy, 15 (6.0%) patients received one
cycle, 14 (5.6%) patients two cycles, 12 (4.8%) patients three cycles,
14 (5.6%) patients four cycles, 8 (3.2%) patients five cycles, and 18
(7.1%) patients six cycles.
In most of the cases (72.3%), the reason for treatment
discontinuation was the patients’ wish to stop therapy.
Toxicity-induced dose reduction of 5-FU was performed
according to the protocol in 44 (17.5%) patients.
Tumour relapse
To date, 83 of the 500 patients have relapsed. Tumour relapse, as
defined by occurrence of metastatic disease or local recurrence,
was documented in 35 of 252 patients (13.9%) on chemotherapy
and in 48 of 248 patients (19.4%) in the control group. In
univariate analysis, the relative risk of relapse in the patient group
treated with adjuvant chemotherapy (study arm 1) was lower than
in the patient group that had received no adjuvant chemotherapy
(study arm 2); however, the difference was statistically not
significant (HR 0.69, 95% CI 0.45–1.06, w
2-test: P¼0.09).
Kaplan–Meier curves for relapse-free survival are shown in
Figure 1.
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Figure 1 Relapse-free survival: adjuvant chemotherapy with 5-fluorouracil (5-FU)/leucovorin (LV) vs surveillance.
Table 1 Reasons for ineligibility of patients in the two study arms
5-FU/LV Surveillance
nn
Violation of inclusion criteria
Missing or withdrawn informed consent 8 14
Inadequate removal of locoregional
lymph nodes
01
Metastases in locoregional lymph nodes 5 2
Missing examinations excluding
metastatic disease
20
Severe concomitant disease 0 1
Total number of patients ineligible 17 18
5-FU¼5-fluorouracil; LV¼leucovorin.
Table 2 Patient and tumour characteristics
5-FU/LV Surveillance
n (%) n (%) P-value
Number of patients 252 (50.4) 248 (49.6)
Median age (years) 64.5 65.4 0.60
Age range 28.5–79.3 30.0–79.7
Male/female 137/115 (54.4/
45.6)
134/114 (54.0/
46.0)
0.94
T category 0.95
T3 217 (86.1) 214 (86.3)
T4 35 (13.9) 34 (13.7)
Grading 0.71
G1 and G2 204 (81.0) 204 (82.3)
G3 and G4 48 (19.0) 44 (17.7)
Tumour localisation 0.85
Caecum and right colon 76 (30.2) 69 (27.8)
Left colon and sigmoid 122 (48.4) 124 (50.0)
Flexures and transverse colon 54 (21.4) 55 (22.2)
Median number of resected
lymph nodes
17 17 0.82
5-FU¼5-fluorouracil; LV¼leucovorin.
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Disease-free survival was statistically not significantly different
between patients on the surveillance arm and those treated with
adjuvant 5-FU/LV (76 events in the surveillance arm, 75 events in
the chemotherapy arm; HR 0.95, 95% CI 0.69–1.31, w
2-test:
P¼0.77).
Overall survival
Up to now, 113 of 500 evaluable patients have died: 55 of 252
patients (21.8%) on the chemotherapy arm (study arm 1) and 58 of
248 patients (23.4%) in the surveillance group (study arm 2). There
was no statistically significant difference in OS between the two
treatment arms (HR 0.88, 95% CI 0.61–1.27, w
2-test: P¼0.49).
Kaplan–Meier curves for OS are presented in Figure 2.
Cancer-specific survival
In 71 patients of the entire study population, death was related to
colon cancer.
Colon cancer-related death was documented in 33 patients
(13.1%) on the chemotherapy arm (study arm 1) and in 38 patients
(15.3%) on the control arm (study arm 2). The relative risk for
colon cancer-related death was not statistically significantly
different between the two study arms (HR 0.83, 95% CI 0.52–1.33,
w
2-test: P¼0.44).
Kaplan–Meier curves for cancer-specific survival are shown in
Figure 3.
Additional analyses on a total of 513 patients, also including 13
randomised patients who were not eligible, but who had signed
and did not withdraw informed consent, did not change the
results. There was no statistically significant difference between the
two study arms in relapse-free survival (HR 0.68, 95% CI 0.44–
1.05, P¼0.08), DFS (HR 0.96, 95% CI 0.70–1.32, P¼0.81),
OS (HR 0.89, 95% CI 0.62–1.29, P¼0.55), or cancer-specific
survival (HR 0.82, 95% CI 0.51–1.30, P¼0.39).
Multivariate analyses of prognostic factors
Cox regression analysis evaluating prognostic parameters for
tumour relapse, as defined by occurrence of metastatic disease or
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Figure 2 Overall survival: adjuvant chemotherapy with 5-fluorouracil (5-FU)/leucovorin (LV) vs surveillance.
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Figure 3 Cancer-specific survival: adjuvant chemotherapy with 5-fluorouracil (5-FU)/leucovorin (LV) vs surveillance.
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slocal recurrence, demonstrated the number of surgically removed
lymph nodes as statistically significant prognostic factor for
tumour relapse. The risk for tumour relapse was significantly
lower in patients with more than 12 lymph nodes removed. The
impact of tumour localisation at caecum and right colon on the
risk of tumour relapse was of borderline significance (P¼0.06).
Patients with tumours located in caecum and right colon had a risk
of tumour relapse that was 1.55 times that of patients with tumours
in the left colon and sigmoid or in flexures and transverse colon.
Age, gender, tumour size, grading, and tumour localisation at
flexures and transverse colon had no significant impact on the risk
of tumour relapse.
Cox regression analysis examining prognostic factors for DFS
revealed age and again the number of surgically removed lymph
nodes, and tumour localisation at caecum and right colon as
significant prognostic factors. The risk for a DFS-relevant event
increased by 4% with each additional year of patients’ age at the
time of randomisation. Gender, grading, tumour size, and tumour
localisation at flexures and transverse colon did not significantly
influence DFS in the multivariate analysis.
With regard to OS, age, the number of surgically removed lymph
nodes, and again tumour localisation at caecum and right colon
were found to be significant prognostic variables. Gender, tumour
size, grading, and tumour localisation at flexures and transverse
colon demonstrated no significant impact on OS in the Cox model.
Cox analysis of prognostic factors for cancer-specific survival
again revealed the number of surgically removed lymph nodes and
tumour localisation at caecum and right colon as the only
statistically significant parameters.
The results of multivariate analyses of prognostic factors for
tumour relapse, DFS, OS, and cancer-specific survival are shown in
Tables 3–6.
Toxicity
In 4.5% of the patients, grade 3 and grade 4 toxicities were
documented during adjuvant chemotherapy with 5-FU/LV. The
distribution of grade 3 and grade 4 toxic effects is shown in
Table 7.
DISCUSSION
The results of the present trial comparing adjuvant chemotherapy
with 5-FU/LV to surveillance after curative surgery for stage II
colon cancer demonstrated a non-significant reduction of the
relative risk for tumour relapse in patients on the chemotherapy
arm. The results of our trial did not demonstrate a significant
impact of adjuvant chemotherapy with 5-FU/LV on DFS and OS in
patients with stage II colon cancer. Previous studies investigating
a possible survival benefit gained by adjuvant chemotherapy in
patients with stage II colon cancer have resulted in controversial
findings. Inter-group trial INT-0035 randomised patients with
stage II and stage III colon cancer to either 5-FU/levamisole or
surgery alone. The trial revealed a significant survival benefit in
patients with stage III colon cancer treated with adjuvant
chemotherapy, but no statistically significant survival difference
between the chemotherapy and surgery-alone arm within the small
group of patients with stage II disease (Moertel et al, 1990, 1995).
Between 1977 and 1990, the NSABP conducted four adjuvant
chemotherapy trials in patients with stage II and III colon cancer.
These trials compared different adjuvant chemotherapy regimens
with one another or with surgery alone (Wolmark et al, 1988, 1990,
1993, 1999). A pooled analysis comparing the best treatment arm
with the inferior arm of each of these trials revealed a 30%
reduction in overall mortality and an absolute survival benefit of
5% for patients with stage II disease, regardless of presence or
absence of high-risk parameters, such as bowel obstruction,
perforation, or extension to adjacent organs (Mamounas et al,
1999).
Whereas the results of the NSABP pooled analysis clearly
suggested to recommend adjuvant chemotherapy to patients with
stage II colon cancer, the data of another pooled analysis,
conducted by the IMPACT B2 investigators, did not support the
Table 3 Multivariate analysis: significant prognostic factors for tumour
relapse
HR 95 % CI P-value
Number of resected lymph nodes 0.44 0.28–0.68 o0.01
Tumour located in caecum and right colon 1.55 0.98–2.44 0.06
HR¼hazard ratios; CI¼confidence interval. For the HR the reference category for
categorical covariates was caecum and right colon for localisation of tumour, 412
lymph nodes for number of resected lymph nodes.
Table 4 Multivariate analysis: significant prognostic factors for DFS
HR 95 % CI P-value
Age 1.04 1.02–1.05 o0.01
Number of resected lymph nodes 0.59 0.42–0.82 o0.01
Tumour located in caecum and right colon 1.64 1.17–2.28 o0.01
HR¼hazard ratios; CI¼confidence interval. For the HR the reference category for
categorical covariates was caecum and right colon for localisation of tumour, 412
lymph nodes for number of resected lymph nodes.
Table 5 Multivariate analysis: significant prognostic factors for OS
HR 95 % CI P-value
Age 1.05 1.05–1.07 o0.01
Number of resected lymph nodes 0.49 0.34–0.72 o0.01
Tumour located in caecum and right colon 1.81 1.24–2.66 o0.01
HR¼hazard ratios; CI¼confidence interval. For the HR the reference category for
categorical covariates was caecum and right colon for localisation of tumour, 412
lymph nodes for number of resected lymph nodes.
Table 6 Multivariate analysis: significant prognostic factors for cancer-
specific survival
HR 95 % CI P-value
Number of resected lymph nodes 0.54 0.33–0.88 0.01
Tumour located in caecum and right colon 1.68 1.03–2.74 0.04
HR¼hazard ratios; CI¼confidence interval. For the HR the reference category for
categorical covariates was caecum and right colon for localisation of tumour, 412
lymph nodes for number of resected lymph nodes.
Table 7 Grade 3 and 4 toxicities of 245 patients with toxicity data
available on study arm 1
n %
Nausea 4 1.6
Diarrhoea 6 2.5
Stomatitis 0 0
Fever 0 0
Leucopenia 0 0
Thrombopenia 1 0.4
Alopecia 0 0
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disease. The IMPACT B2 analysis included 1016 patients with stage
II colon cancer in five separate trials who were randomised to
adjuvant chemotherapy with 5-FU/LV or observation after curative
surgery. After a median follow-up duration of 5.75 years, no
statistically significant difference in event-free survival or OS was
observed between the two treatment categories (IMPACT B2
Investigators, 1999).
The American Society of Clinical Oncology (ASCO) published
recommendations on adjuvant chemotherapy for stage II colon
cancer in 2004 (Benson et al, 2004). These recommendations were
guided by a literature-based meta-analysis including 37 trials and
11 meta-analyses, altogether demonstrating a small improvement
of DFS by 5–10%, but no statistically significant improvement of
OS by adjuvant chemotherapy (Figueredo et al, 2004). The authors
of the ASCO recommendations thus concluded that direct evidence
from randomised controlled trials does not support the routine use
of adjuvant chemotherapy in patients with stage II colon cancer.
Results of the Quick and Simple and Reliable (QUASAR) 1 trial,
investigating the impact of adjuvant chemotherapy on survival in
3238 patients with colorectal cancer (91% stage II), demonstrated
for patients with stage II disease a small, but statistically significant
absolute 5-year survival benefit of 2.9% on the chemotherapy arm
after a median follow-up of 4.2 years. The authors of this presently
largest single trial in stage II colon cancer concluded that
‘chemotherapy produces a small (1–5%) survival benefit for stage
II patients, sufficient to outweigh the inconvenience and cost for
high-risk and younger patients’ (Gray et al, 2004).
The Multicenter International Study of Oxaliplatin/5-FU/
Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
compared the efficacy of adjuvant 5-FU/LV/oxaliplatin to 5-FU/LV
in patients with stage II and III colon cancer. Results of the
MOSAIC trial demonstrated a statistically significant improvement
of DFS in the 5-FU/LV/oxaliplatin arm in both the subgroups of
patients with stage II and those with stage III disease (Andre et al,
2004).
These data demonstrate that adjuvant chemotherapy in stage II
colon cancer is effective, though the effect on survival is small. In
our trial, adjuvant chemotherapy decreased the relative risk for
tumour relapse, yet with no significant impact on DFS or OS. This
trial was designed to detect an absolute difference in OS of 10%
between the two study arms. In addition, the planned patient
number was not reached, a result being that the trial is not
sufficiently powered to detect the small survival difference as
observed in other trials. Due to the fact that the target number of
patients recruited was not reached, the power to detect a difference
in OS of 10% was reduced from 85 to 70.5%. The power of this trial
to detect an absolute difference in 5-year survival of 2.9% as
observed in the QUASAR 1 trial is 16.6%.
Multivariate analysis in the present trial showed the number of
lymph nodes resected to be a significant prognostic factor for the
risk of tumour relapse, DFS, OS, and cancer-specific survival.
Patients with more than 12 nodes analysed exhibited a significantly
better prognosis compared to patients in whom 12 or less lymph
nodes had been examined. This association between the number of
lymph nodes resected and prognosis of patients with node-
negative colon cancer confirms the results emanating from
previous studies (Le Voyer et al, 2003; Chen and Bilchik, 2006).
A possible explanation for this finding is that patients with fewer
nodes analysed might be understaged and at higher risk for
residual tumour disease after surgery.
In conclusion, the results of this prospective randomised trial
with limited power to detect relevant differences between the study
arms failed to demonstrate a statistically significant impact of
adjuvant chemotherapy with 5-FU/LV on DFS and OS in patients
following curative surgery for stage II colon cancer. Thus, the
findings of this trial do not support the general use of adjuvant
chemotherapy in all patients with stage II colon cancer.
REFERENCES
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T,
Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de
Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/
Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant
treatment for colon cancer. N Engl J Med 350: 2343–2351
Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn
PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers
M, Charette M, Haller DG (2004) American Society of Clinical Oncology
recommendations on adjuvant chemotherapy for stage II colon cancer.
J Clin Oncol 22: 3408–3419
Chen SL, Bilchik AJ (2006) More extensive nodal dissection improves
survival for stages I to III of colon cancer: a population-based study.
Ann Surg 244: 602–610
Cox DR (1972) Regression models and life-tables. JRS t a tS o c( B )34: 187–220
Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L (2004)
Adjuvant therapy for stage II colon cancer: a systematic review from the
Cancer Care Ontario Program in evidence-based care’s gastrointestinal
cancer disease site. J Clin Oncol 22: 3395–3407
Gray RG, Barnwell J, Hills R, McConkey C, Williams N, Kerr D (2004) for
the QUASAR Collaborative Group: a randomized study of adjuvant
chemotherapy vs observation including 3238 colorectal cancer patients.
Proc Am Soc Clin Oncol 22: 245
International Multicentre Pooled Analysis of B2 Colon Cancer Trials
(IMPACT B2) Investigators (1999) Efficacy of adjuvant fluorouracil and
folinic acid in B2 colon cancer. J Clin Oncol 17: 1356–1363
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer
Statistics, 2003. CA Cancer J Clin 53: 5–26
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete
observations. J Am Stat Assoc 53: 457–481
Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano
PJ, Haller DG (2003) Colon cancer survival is associated with increasing
number of lymph nodes analyzed: a secondary survey of intergroup trial
INT-0089. J Clin Oncol 21: 2912–2919
Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J,
Rockette H (1999) Comparative efficacy of adjuvant chemotherapy in
patients with Dukes’ B vs Dukes’ C colon cancer: results from four
National Surgical Adjuvant Breast and Bowel Project adjuvant studies
(C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349–1355
Mantel N (1966) Evaluation of survival data and two new rank order
statistics arising in its consideration. Cancer Chemother Rep 50: 163–170
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ,
Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH,
Maillard JA (1990) Levamisole and fluorouracil for adjuvant therapy of
resected colon carcinoma. N Engl J Med 322: 352–358
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM,
Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH,
Mailliard JA (1995) Fluorouracil plus levamisole as effective adjuvant
therapy after resection of stage III colon carcinoma: a final report. Ann
Intern Med 122: 321–326
Nauta R, Stablein DM, Holyoke ED (1989) Survival of patients with stage B2
colon carcinoma. The Gastrointestinal Tumor Study Group experience.
Arch Surg 124: 180–182
Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The
global picture. Eur J Cancer 37: S4–S66
Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for
prognostic factors in the controlled clinical trial. Biometrics 31: 103–115
Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER,
Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J,
Cruz A, Dimitrov N, Jochimsen P (1988) Postoperative adjuvant
chemotherapy or BCG for colon cancer: results from NSABP protocol
C-01. J Natl Cancer Inst 80: 30–36
Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER,
Jones J, Mamounas EP, Ore L, Petrelli NJ (1993) The benefit of
Adjuvant chemotherapy in stage II colon cancer
W Schippinger et al
1026
British Journal of Cancer (2007) 97(8), 1021–1027 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sleucovorin-modulated fluorouracil as postoperative adjuvant therapy for
primary colon cancer: results from National Surgical Adjuvant Breast
and Bowel Project protocol C-03. J Clin Oncol 11: 1879–1887
Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL,
Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999)
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin,
fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in
patients with Dukes’ B and C carcinoma of the colon: results from National
Surgical Adjuvant Breast and Bowel Project C-04. JC l i nO n c o l17: 3553–3559
Wolmark N, Rockette H, Wickerham DL, Fisher B, Redmond C, Fisher ER,
Potvin M, Davies RJ, Jones J, Robidoux A (1990) Adjuvant therapy of
Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil
hepatic infusion: preliminary results of National Surgical Adjuvant Breast and
Bowel Project Protocol C-02. JC l i nO n c o l8: 1466–1475
Appendix
Apart from the authors of this article, members of the Austrian
Breast and Colorectal Cancer Study Group participating in this
trial included the following:
H Bacher, R Bartsch, T Bauernhofer, A Berger, J Berger, M
Bergmann, C Bittermann, O Bo ¨ckl, K Czerwenka, D Depisch, W
Draxler, P Dubsky, A El-Shabrawi, J Freisinger, KM Freudenthaler,
K Haider, M Hanak, B Hartmann, H Hauser, J Hebenstreit, E Hell,
G Hofmann, D Hussian, G Jatzko, C Kainz, D Kandioler, A
Kasparek, C Kiendler, R Kolb, P Konstantinuik, G Kosina, A
Kretschmer, P Krippl, S Kriwanek, L Kronberger, I Kuehrer, I
Kuss, W Kwasny, M Lang, N Langer, U Langsenlehner, A Lenauer,
G Locker, G Loncsar, H Ludwig, I Luisser, H Luschnik, K Mach, P
Mayer, G Michlmayr, HJ Mischinger, M Mittlbo ¨ck, E Moritz, A
Obermair, E Nessler, T Niernberger, D Nitsche, D O ¨fner, E
Ostermann, I Papadi, C Papp, A Pertl, J Pfeifer, F Ploner, U
Pluschnig, R Pointner, M Prochaska, R Pruscha, R Punzengruber,
C Rass, A Reiner, G Reiner, S Reinisch, M Riegler, S Roka, G
Rosanelli, M Rudas, G Russ, P Sandbichler, R Schandalik, M
Schemper, M Schmid, W Schwaiger, U Sevelda, H Spoula, T Stein,
P Steindorfer, A Stift, H Sto ¨ger, C Tausch, B Teleky, K To ¨gel, G
Tschurtschenthaler, M Umlauft, N Vavra, P Wagner, G Wahl, M
Wehrschu ¨tz, W Weitzer, C Wenzel, B Zeh, R Zwrtek, and C
Zielinski.
Adjuvant chemotherapy in stage II colon cancer
W Schippinger et al
1027
British Journal of Cancer (2007) 97(8), 1021–1027 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s